Monday, November 30 | 8:00 a.m.-9:00 a.m. | M1-SSNMMI02-8 | Room S405
An orally administered encapsulated fatty acid radiotracer successfully images thoracic duct lymphatic flow with anatomic precision on PET/CT, suggest preliminary findings from a first-in-human study presented in this session.
Presenter Robert Romero, MD, of the University of Pennsylvania, and colleagues tested a long-chain fatty acid analog transported via intestinal lymphatics called F-18 FTHA (F-18 fluoro-6-thia-heptadecanoic acid) in five healthy volunteers. Participants were given an average dose of 1.5 mCi (range 1.3-1.6) of F-18 FTHA that was encapsulated with canola oil, followed by a high-calorie drink (Ensure Plus) 10 minutes later to stimulate chylomicron formation. Thirty minutes post capsule administration, subjects underwent dynamic PET imaging for 60 minutes (Penn PET Explorer). Three additional, 30-minute scans were acquired at 2, 3, and 4 hours post-administration.
All five subjects showed thoracic duct visualization from cisterna chyli to the left jugulovenous angle. Two demonstrated duplicated proximal variant anatomy. Mean time to peak uptake was 2 hours and 25 minutes (half-peak: 75 minutes). Radiotracer esophageal reflux obscured the thoracic duct in three subjects, mildly in 2 and moderately in one.
Most lymphatic disorders affect the thoracic duct, the group noted. While percutaneous imaging advances have enabled interventional radiology therapies, a noninvasive method for defining thoracic duct anatomy and measuring flow for treatment planning has remained elusive, they added.
"As a next step, we will proceed with both pre- and post-operative imaging of 10 subjects with known [thoracic duct] pathology to assess the potential impact of encapsulated F-18 FTHA PET/CT on diagnosis and treatment response assessment in patients with lymphatic disease,” the authors wrote.
Romero is a resident training in nuclear medicine and interventional radiology. Stop by this session to see the images.



